{"schema_version":"1.0","type":"article","title":"OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間","url":"https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity.md","lang":"zh-Hant","date":"2026-05-24","publish_at":"2026-05-24T10:30:00+08:00","updated_at":"2026-05-24","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","GLP-1","CNS","FDA","OX2R"],"summary":"【 OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間】中樞神經系統藥物開發，很久沒有出現一個這麼清楚、這麼有生物學邏輯、又這麼接近臨床突破的靶點。這個靶點就是 Orexin Recept","key_points":[],"facts":[],"sections":["01｜NT1 不是犯困，而是大腦清醒開關失靈","02｜OX2R 為什麼是關鍵？因為它更像「清醒穩定器」","03｜TAK-994：第一道曙光，也第一個安全性警訊","04｜TAK-861：如果安全性成立，NT1 標準治療可能被改寫","05｜OX2R 的想像空間，不只 NT1，而是整個 sleep-wake disorder 市場","06｜全球藥廠為什麼開始搶 OX2R？因為它可能是下一個 CNS 平台級靶點","07｜但 OX2R 還有三個關鍵風險，不能只看想像空間"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1","source":"","date":"","url":""},{"title":"AbstractStudy Objectives. The diagnosis of narcolepsy type 1 (NT1) is based upon the presence of cataplexy and/or a cerebrospinal fluid (CSF) hypocretin-1/","source":"","date":"","url":""},{"title":"academic.oup.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Lock","source":"","date":"","url":""},{"title":"Narcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management. This study aimed to provide evidence supporting the safety of pharmacological treatment for narcolepsy. Five-year data on pitolisant, ...","source":"","date":"","url":""},{"title":"pmc.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1","source":"NEJM","date":"","url":""},{"title":"Narcolepsy type 1 is caused by severe loss or lack of brain orexin neuropeptides. We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor 2–selective agonis...","source":"","date":"","url":""},{"title":"www.nejm.org","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"YouTube","source":"","date":"","url":""},{"title":"Findings Indicate Orexin Receptor 2 as Promising Novel Biologic Target for Future Development of Narcolepsy Type 1 Treatments","source":"","date":"","url":""},{"title":"www.takeda.com","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"YouTube","source":"","date":"","url":""},{"title":"Explore the Phase 2b trial results of oveporexton (TAK-861) published in NEJM, showing significant improvements in excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of","source":"","date":"","url":""},{"title":"www.takeda.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間","url":"https://drugnews.com.tw/assets/articles/ox2r-cns-narcolepsy-opportunity/dcard-01.webp"},{"alt":"Dcard 原圖：OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間","url":"https://drugnews.com.tw/assets/articles/ox2r-cns-narcolepsy-opportunity/dcard-02.png"},{"alt":"Dcard 原圖：OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間","url":"https://drugnews.com.tw/assets/articles/ox2r-cns-narcolepsy-opportunity/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/ox2r-cns-narcolepsy-opportunity/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-24）。OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間。https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-24-ox2r-cns-narcolepsy-opportunity-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}